Miltenyi Biomedicine

Miltenyi Biomedicine, based in Bergisch Gladbach, Germany, is a cell therapy company and part of Miltenyi Biotec (Miltenyi group). Develops personalised cell and gene therapies, specifically CAR-T cell therapies for oncology and autoimmune diseases; part of the Miltenyi group alongside Miltenyi Biotec. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489 (DALY II USA/ MB-CART2019.1 for DLBCL), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.